Shire Gets Advisory Committee Support For Firazyr Self-Administration Claim
Executive Summary
Shire will enter discussions with FDA on labeling for its hereditary angioedema drug Firazyr (icatibant) with backing from an advisory panel for a claim to allow patients to self-administer the product, which is delivered through subcutaneous injection.
You may also be interested in...
FDA Relies On Experience To Judge Firazyr Self-Administration
The Center for Devices and Radiological Health recommended a delay in approving Firazyr until a human factors study could be conducted to rule out risks associated with the self-administration device, but CDER reviewers concluded that experience with the device in clinical trials and real life was sufficient to demonstrate safety.
FDA Asks If PRO Used For Shire's Firazyr Is Clinically Meaningful
FDA finds no faults with self-administration for the hereditary angioedema drug as it takes the new molecular entity to a June 23 advisory panel.
Jerini’s Icatibant Falters in U.S., Wins In Europe
FDA rejects orphan drug for hereditary angioedema, paving way for rivals to gain an edge.